Interleukin (IL) 35 belongs to the IL-12 family. IL-35 has been shown in studies to be an essential anti-inflammatory cytokine that inhibits effector T-cell function. The goal of this study was to look at serum IL-35 levels in systemic sclerosis (SSc) patients and see whether there was a link between them and clinical findings. In a single centre during a 5-month period, we performed a cross-sectional analysis on 70 SSc patients and 29 healthy volunteers. The modified Rodnan skin score was used to assess the extent of skin fibrosis. Medsger disease severity ratings were used to measure disease severity. A commercial enzyme-linked immunosorbent test (ELISA) kit was used to detect serum IL-35. The researchers looked at the connection between IL-35 levels and clinical and laboratory markers. Mann-Whitney U test was used to compare parameters between groups. Spearman correlation coefficient was used to assess for correlation. Serum IL-35 levels in SSc patients were considerably greater than in healthy controls. There was no link seen between serum IL-35 levels and organ involvement. Serum IL-35 levels correlated negatively with Medsger disease severity score, modified Rodnan skin score, and C-reactive protein. There was no link discovered between IL-35 and illness duration or erythrocyte sedimentation rate.
In contrast to prior research, our study found that IL-35 levels were greater in SSc patients, and it was the first to indicate that IL-35 levels did not rise in SSc patients with pulmonary fibrosis.
